glp-1 and chronic kidney disease Combination therapy as a new standard of care in diabetic non-diabetic Glucagon-like Peptide Receptor Agonists and

GLP-1 peptides for weight loss act in research through the GLP-1 receptor, which is involved in regulating satiety, gastric emptying, and glucose-dependent insulin secretion

The Smooth Movers (Stool Softeners for Mild GLP-1 Constipation): These agents, like docusate sodium, work by reducing the surface tension of stool, allowing water and fats to penetrate it more easily, resulting in softer stool and potentially easing mild constipation from GLP-1 drugs

Dulaglutide (Trulicity): A long-acting GLP-1 RA consisting of two GLP-1 analog sequences covalently linked to an Fc fragment, which extends its half-life to ~5 days

Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes

3oxoglutaric acid) in children with autism and gastrointestinal symptoms, suggesting associations with gut microbial alterations

1B and S1)